Vertex halts development of diabetes cell therapy after trial failure

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not produce sufficient levels of insulin.